Briacell Therapeutics
BCTX
20 hedge funds and large institutions have $17M invested in Briacell Therapeutics in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.
1,614% more call options, than puts
Call options by funds: $7.61M | Put options by funds: $444K
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
25% more funds holding
Funds holding: 16 → 20 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.49% less ownership
Funds ownership: 21.61% → 19.12% (-2.5%)
49% less capital invested
Capital invested by funds: $33.5M → $17M (-$16.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
+$1.68M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$737K |
| 3 |
Jane Street
New York
|
+$331K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$182K |
| 5 |
BCM
Bluefin Capital Management
New York
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGP
Leonard Green & Partners
Los Angeles,
California
|
-$5.07M |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$916K |
| 3 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$889K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$260K |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$154K |
BCTX Hedge Fund Activity: Q2 2022 in Review
20 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q2 2022, worth a combined $17M — down 49% from $33.5M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BCTX positions and 4 closed out — a net gain of 4 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was K.J. Harrison & Partners, adding an estimated $1.68M. The largest seller was Leonard Green & Partners, exiting entirely with an estimated $5.07M sold.
- 20 institutional investors held Briacell Therapeutics (BCTX) as of Q2 2022, up from 16 in Q1 2022.
- Funds reported $17M of Briacell Therapeutics stock for Q2 2022, down 49% quarter-over-quarter.
- 8 funds opened new Briacell Therapeutics positions in Q2 2022 and 4 closed out, a net change of +4 holders.
- The largest Briacell Therapeutics buyer in Q2 2022 was K.J. Harrison & Partners, an estimated $1.68M added.
- The largest Briacell Therapeutics seller in Q2 2022 was Leonard Green & Partners, an estimated $5.07M sold.
Based on aggregated 13F filings for Q2 2022.